抗真菌药物的联合应用

摘要/Abstract

摘要： 目前真菌感染,特别是免疫缺陷患者中侵入性真菌感染的发病率和死亡率在不断增加,但现有抗真菌药物可选择范围小、毒副作用大而且耐药情况日渐严重。联合用药这一概念的提出,给耐药株及严重性真菌感染提供了新的治疗途径,并且已在临床中广泛运用。该文对不同种类抗真菌药物联用的研究成果及作用机制做一综述。

关键词: 抗真菌药物, 联合用药, 协同作用

Abstract: Nowadays, morbidity and mortality of invasive fungal infection are increasing, especially among immunocompromised patients. However,the range of choices of existing antifungal drugs, most of which have drug toxicities and drug resistance, are limited.The combination use of antifungal drugs which has gradually applied to the clinic provides a new approach for the resistant strains infection and severe fungal infection. This review is about the effects and mechanisms of the combination therapy of different antifungal drugs.

Key words: antifungal drugs, combination therapy, synergistic effect

中图分类号:

R978.5

魏冰, 刘锦燕, 项明洁. 抗真菌药物的联合应用[J]. 中国真菌学杂志, 2013, 8(1): 61-64.

WEI Bing, LIU Jin-yan, XIANG Ming-jie. Combination of antifungal therapy[J]. Chinese Journal of Mycology, 2013, 8(1): 61-64.

参考文献

[1] Samaranayake YH,Samaranayake LP,Yeung KW.Evaluation of polyene-azole antagonism in liquid cultures of Candida albicans using an automated turbidometric method[J]. Chemotherapy,2001,47(4):279-291.
[2] Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy[J]. Antimicrob Agents Chemother,2004,48(3):693-715.
[3] Kontoyiannis DP, Lewis RE, Sagar N, et al. Itraconazole amphotericin B antagonism in Aspergillus fumigatus:an E-test-based strategy[J]. Antimicrob Agents Chemother,2000,44(10):2915-2918.
[4] Chaturvedi V, Ramani R, Ghannoum MA,et al. Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei[J]. Antimicrob Agents Chemother,2008,52(4):1500-1502.
[5] Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects[J]. Clin Infect Dis,2003,36(10):1221-1228.
[6] Rieger CT, Ostermann H, Kolb HJ,et al.A clinical cohort trial of antifungal combination therapy:efficacy and toxicity in haematological cancer patients[J]. Ann Hematol,2008,87(11):915-922.
[7] Pappas PG, Chetchotisakd P, Larsen RA, et al.A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis[J]. Clin Infect Dis,2009,48(12):1775-1783.
[8] Barchiesi F, Schimizzi AM, Najvar LK, et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans[J].Antimicrob Agents Chemother, 2001,45(5):1355-1359.
[9] Girmenia C, Venditti M, Martino P. Fluconazole in combination with in the treatment of fluconazole-resistant Candida infections[J]. Diagn Microbiol Infect Dis, 2003,46(3):227-231.
[10] Nussbaum JC, Jackson A, Namarika D,et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi[J]. Clin Infect Dis, 2010,50(3):338-344.
[11] Saag MS, Graybill RJ, Larsen RA,et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America[J]. Clin Infect Dis,2000,30(4):710-718.
[12] Shalit I, Shadkchan Y, Samra Z, et al. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points[J]. Antimicrob Agents Chemother,2003,47(4):1416-1418.
[13] Nishi I, Sunada A, Toyokawa M, et al. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole,amphotericin B, and flucytosine against clinical isolates of Candida species[J]. J Infect Chemother, 2009,15(1):1-5.
[14] López-Ciudad V, Castro-Orjales MJ, León C, et al. Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole[J]. BMC Infect Dis,2006,6:73.
[15] Calvo E, Pastor FJ, Mayayo E,et al. In vitro and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus[J]. Antimicrob Agents Chemother,2011,55(3):1290-1292.
[16] Marr KA, Boeck M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis[J]. Clin Infect Dis,2004,39(6):797-802.
[17] Barchiesi F, Spreghini E, Tomassetti S, et al.Caspofungin in combination with amphotericin B against Candida parapsilosis[J]. Antimicrob Agents Chemother, 2007,51(3):941-945.
[18] Oz Y, Dag I, Kiraz N. Broth microdilution and time-kill testing of caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei[J]. Mycopathologia,2012,173(1):27-34.
[19] Traunm黮ler F, Popovic M, Konz KH, et al.Efficacy and safety of current drug therapies for invasive aspergillosis[J]. Pharmacology,2011,88(3-4):213-224.
[20] Maertens J, Glasmacher A, Herbrecht R, et al.Multicenter,noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis[J]. Cancer,2006,107(12):2888-2897.
[21] Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (COMBISTRAT trial)[J].Cancer,2007, 110(12): 2740-2746.
[22] Schwarz P, Janbon G, Dromer F, et al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans[J]. Antimicrob Agents Chemother,2007,51(1):383-385.
[23] Schwarz P, Dromer F, Lortholary O, et al.Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis[J].Antimicrob Agents Chemother,2006,50(1):113-120.
[24] Brouwer AE, Rajanuwong A, Chierakul Wet, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial[J]. Lancet 2004, 363(9423): 1764-1767.
[25] Dromer F, Bernede-Bauduin C,Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis[J]. PLoS One,2008,3(8):e2870.
[26] Cantón E, Pemán J, Gobernado M, et al. Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods[J]. Antimicrob Agents Chemother, 2005,49(4):1593-1596.
[27] Biancalana FS, Lyra L, Schreiber AZ. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds[J]. Antimicrob Agents Chemother,2011,55(9):4485-4487.
[28] Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, et al. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine[J]. Diagn Microbiol Infect Dis,2008,62(4):443-446.
[29] Guo N, Ling G, Liang X, et al. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans[J]. Mycoses, 2011,54(5):400-406.
[30] Kobayashi T, Kakeya H, Miyazaki T, et al. Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis[J]. Jpn J Infect Dis, 2011,64(4):292-296.